Zobrazeno 1 - 10
of 149
pro vyhledávání: '"Helmut Ostermann"'
Autor:
Amal AlZahmi, Irena Cenzer, Ulrich Mansmann, Helmut Ostermann, Sebastian Theurich, Tobias Schleinkofer, Karin Berger
Publikováno v:
PLoS ONE, Vol 17, Iss 7, p e0271754 (2022)
ObjectivesTo assess the usability of German hospital administrative claims data (GHACD) to determine inpatient management patterns, healthcare resource utilization, and quality-of-care in patients with multiple myeloma (PwMM).MethodsBased on German t
Externí odkaz:
https://doaj.org/article/6a832de5dcd042c5a94411b41f94238c
Autor:
Felix C. Koehler, Oliver A. Cornely, Hilmar Wisplinghoff, Astrid C. Schauss, Jon Salmanton-Garcia, Helmut Ostermann, Maren Ziegler, Petra Bacher, Alexander Scheffold, Regina Alex, Anne Richter, Philipp Koehler
Publikováno v:
Frontiers in Microbiology, Vol 9 (2018)
Background: Blood or tissue culture or histology prove invasive Candida infection, but long time to result, limited feasibility and sensitivity call for new approaches. In this pilot project, we describe the diagnostic potential of quantitating Candi
Externí odkaz:
https://doaj.org/article/129e6ff20e884ba58a0b8ebfe802a62e
Publikováno v:
Biologics: Targets & Therapy, Vol 2010, Iss default, Pp 139-145 (2010)
Andreas Rank, Oliver Weigert, Helmut OstermannMedizinische Klinik III – Grosshadern, Klinikum der Ludwig Maximilians-Universitaet Munich, Munich, GermanyAbstract: Traditionally, anti-platelet autoantibodies accelerating platelet clearance from the
Externí odkaz:
https://doaj.org/article/22dad4fc01334c3e9df59507aa98af48
Autor:
Christoph Mueller-Loebnitz, Helmut Ostermann, Anke Franzke, Juergen Loeffler, Lutz Uharek, Max Topp, Hermann Einsele
Publikováno v:
Interdisciplinary Perspectives on Infectious Diseases, Vol 2013 (2013)
Patients with allogeneic stem cell transplantation (SCT) have a high risk of invasive fungal infections (IFIs) even after neutrophil regeneration. Immunological aspects might play a very important role in the IFI development in these patients. Some d
Externí odkaz:
https://doaj.org/article/3f55928a21c54a1aae5984dbec363b30
Autor:
Axel C Matzdorff, Gabriele Arnold, Abdulgabar Salama, Helmut Ostermann, Sonja Eberle, Simone Hummler
Publikováno v:
PLoS ONE, Vol 6, Iss 11, p e27350 (2011)
BACKGROUND: Current guidelines recommend glucocorticoids and splenectomy as standard 1(st) and 2(nd) line treatments for chronic immune thrombocytopenia (ITP). We sought to find out how German ITP-patients are treated with respect to these guidelines
Externí odkaz:
https://doaj.org/article/9d9e4a535a3e4309acfbbdea5f9f3969
Autor:
Karin Berger, Reinhard Henschler, Vanessa Kratzer, Christina Rieger, Georg Wittmann, Helmut Ostermann
Publikováno v:
Oncology Research and Treatment. 45:336-343
Introduction: In Germany, up to 75% of platelet concentrates (PCs) are administered to haematological and oncological patients. Only limited transparency exists on the characteristics of haematological/oncological patients receiving PC transfusions,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fde4ff9f0d42a35721ea18d5d993585b
https://doi.org/10.1159/000522659
https://doi.org/10.1159/000522659
Autor:
Axel Matzdorff, Sonja R. Alesci, Johanna Gebhart, Susanne Holzhauer, Marie Luise Hütter-Krönke, Thomas Kühne, Oliver Meyer, Helmut Ostermann, Ingrid Pabinger, Mathias Rummel, Ulrich J. Sachs, Thomas Stauch, Karolin Trautmann-Grill, Bernhard Wörmann
Publikováno v:
Oncology Research and Treatment.
no Abstract
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65d9e84788c22fd561a57eb7f8af0d2b
https://doi.org/10.1159/000529662
https://doi.org/10.1159/000529662
Autor:
Axel Matzdorff, Sonja R. Alesci, Johanna Gebhart, Susanne Holzhauer, Marie Luise Hütter-Krönke, Thomas Kühne, Oliver Meyer, Helmut Ostermann, Ingrid Pabinger, Mathias Rummel, Ulrich J. Sachs, Thomas Stauch, Karolin Trautmann-Grill, Bernhard Wörmann
Publikováno v:
Oncology research and treatment.
not abstract, please contact Dr. Hentzelt, Publication manager Karger.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a02d60150f91cb891e9656f3fc8721b2
https://pubmed.ncbi.nlm.nih.gov/36572012
https://pubmed.ncbi.nlm.nih.gov/36572012
Autor:
Josée M. Zijlstra, Stefan Balabanov, Carsten Kobe, Hans Theodor Eich, Richard Greil, Julia Meissner, Alden A. Moccia, Teresa V Halbsguth, Volker Diehl, Paul J Bröckelmann, Judith Dierlamm, Ulrich Keller, Bastian von Tresckow, Christian Baues, Michael Fuchs, Annette Plütschow, Helmut Ostermann, Simone Marnitz, Martin Wilhelm, Sonja Martin, Beate Klimm, Julia Thiemer, Peter Borchmann, Thomas Pabst, Johannes Mohm, Michael Hallek, Andreas Rosenwald, Markus Dietlein, Andreas Hüttmann, Martin Vogelhuber, Max S. Topp, Martin Sökler, Andreas Engert, Andrea Kerkhoff, Miriam Ahlborn, Georg Kuhnert
Publikováno v:
The Lancet Oncology, 22(2), 223-234. Lancet Publishing Group
Borchmann, P, Plütschow, A, Kobe, C, Greil, R, Meissner, J, Topp, M S, Ostermann, H, Dierlamm, J, Mohm, J, Thiemer, J, Sökler, M, Kerkhoff, A, Ahlborn, M, Halbsguth, T V, Martin, S, Keller, U, Balabanov, S, Pabst, T, Vogelhuber, M, Hüttmann, A, Wilhelm, M, Zijlstra, J M, Moccia, A, Kuhnert, G, Bröckelmann, P J, von Tresckow, B, Fuchs, M, Klimm, B, Rosenwald, A, Eich, H, Baues, C, Marnitz, S, Hallek, M, Diehl, V, Dietlein, M & Engert, A 2021, ' PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17) : a multicentre, open-label, randomised, phase 3 trial ', The Lancet Oncology, vol. 22, no. 2, pp. 223-234 . https://doi.org/10.1016/S1470-2045(20)30601-X
Strahlentherapie Und Onkologie
Borchmann, P, Plütschow, A, Kobe, C, Greil, R, Meissner, J, Topp, M S, Ostermann, H, Dierlamm, J, Mohm, J, Thiemer, J, Sökler, M, Kerkhoff, A, Ahlborn, M, Halbsguth, T V, Martin, S, Keller, U, Balabanov, S, Pabst, T, Vogelhuber, M, Hüttmann, A, Wilhelm, M, Zijlstra, J M, Moccia, A, Kuhnert, G, Bröckelmann, P J, von Tresckow, B, Fuchs, M, Klimm, B, Rosenwald, A, Eich, H, Baues, C, Marnitz, S, Hallek, M, Diehl, V, Dietlein, M & Engert, A 2021, ' PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17) : a multicentre, open-label, randomised, phase 3 trial ', The Lancet Oncology, vol. 22, no. 2, pp. 223-234 . https://doi.org/10.1016/S1470-2045(20)30601-X
Strahlentherapie Und Onkologie
Background: Combined-modality treatment consisting of chemotherapy and consolidation radiotherapy is standard of care for patients with early-stage unfavourable Hodgkin lymphoma. However, the use of radiotherapy can have long-term sequelae, which is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f13d466acfe65ac8d5c77ff231c4382
https://doi.org/10.1016/s1470-2045(20)30601-x
https://doi.org/10.1016/s1470-2045(20)30601-x
Autor:
Annette M. Rodriguez, Karin Berger, Kenneth E. Covinsky, Helmut Ostermann, Irena Stijacic Cenzer
Publikováno v:
Aging Clinical and Experimental Research
Background Changes in well-being of patients with multiple myeloma (MM) before and after diagnosis have not been quantified. Aims Explore the use of secondary data to examine the changes in the well-being of older patients with MM. Methods We used th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bed96b5e4a4718d899b4e9cfafdaf791
http://europepmc.org/articles/PMC7260254
http://europepmc.org/articles/PMC7260254